Semaglutide has emerged as one of the most sought-after medications for weight loss, driving a surge in online recommendations and unregulated sales of peptides across social media platforms like Facebook and Instagram. According to the World Health Organization (WHO), medications acting on GLP-1 receptors are recognized as a treatment option for adult obesity, provided they are used as part of a comprehensive approach and under medical supervision.
The distinction between internet wellness trends and authorized pharmaceuticals centers on clinical validation and regulatory safety standards. Semaglutide functions by mimicking a natural hormone called GLP-1, which regulates blood sugar and appetite. Manufactured primarily by Danish pharmaceutical company Novo Nordisk and described by Mayo Clinic, GLP-1 is produced in the intestine and brain regions controlling hunger and satiety. Activating GLP-1 receptors stimulates insulin release during high blood glucose events, suppresses glucagon, and slows gastric emptying to increase feelings of fullness.
Authorized Semaglutide Registrations in Costa Rica
According to the Costa Rican Ministry of Health, only two sanitary registrations currently exist for medications containing semaglutide as an active ingredient. Both approved products belong to the Ozempic brand, manufactured by Novo Nordisk: Ozempic Dualdose, registered under number MB-DK-21-00002, and Ozempic Fixdose, registered under number MB-DK-20-00011. Health authorities stress that these treatments require an official prescription from an authorized medical professional following a clinical evaluation, and must be purchased exclusively through licensed pharmacies.
In private Costa Rican pharmacies, weekly doses of authorized Ozempic exceed ₡100,000. Food and Drug Administration (FDA) approved Ozempic in December 2017 to improve glycemic control in adults. Researchers subsequently identified significant weight loss effects during clinical use, prompting Novo Nordisk to develop Wegovy specifically for chronic weight management using distinct dosing regimens and clinical trials tailored to obesity.
Public Healthcare Availability and Regulatory Alerts
Esteban Vega, logistics manager for the Costa Rican Social Security Fund (CCSS), confirmed that semaglutide is not currently distributed through the public healthcare system. The initial rollout will target diabetic patients needing metabolic control and overweight diabetic populations, with subsequent expansion planned for other patient groups meeting specific clinical criteria for overweight management.
High retail costs have driven patients toward unverified online markets. On October 28, 2025, and July 23, 2025, the Ministry of Health issued public health alerts regarding unauthorized products containing semaglutide, tirzepatida, and unapproved peptides sold through social media and rogue websites. Colombian endocrinologist Karen Palacios, medical internist and obesity specialist, warns that efficacy does not equate to safety when seeking weight loss interventions. Palacios emphasized that medical weight management demands structured professional oversight involving multidisciplinary teams rather than self-administered dosing regimens.
Frequently Asked Questions
- What is the difference between Ozempic and Wegovy? Both contain semaglutide, but Ozempic is formulated and approved for type 2 diabetes management, whereas Wegovy is studied and dosed specifically for chronic weight management.
- Can semaglutide be purchased online without a prescription? No. Health authorities state that authorized semaglutide products require a medical prescription and must be acquired only at licensed pharmacies to prevent severe health risks from counterfeit or unregulated peptides.
- Does the public healthcare system in Costa Rica provide semaglutide? As of now, the CCSS does not supply semaglutide, though technical evaluations are underway to incorporate a GLP-1 medication for eligible diabetic and overweight patients in future phases.
Related reading